Overview
Total raised
$15M
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Healthspan Capital | healthspancapital.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 22, 2024 | Этот учёный хочет постепенно заменить ваш мозг | Правительство США только что наняло учёного, который считает, что мы можем победить старение с помощью клонированных тел и обновлений мозга. Американское агентство, занимающееся революционными разработками в области здравоохранения, наняло ... |
| Jul 25, 2024 | Oisín Biotechnologies Holds First Close of $15M Series A Financing | Oisín Biotechnologies, a Seattle, WA-based biotechnology company focused on mitigating the effects of age-related diseases, announced the first close of a $15M in Series A funding. The round was led by AbbVie Ventures. Danjuma Quarless, Ph.... |
| Sep 1, 2022 | Seattle biotech company is the first to receive approval to test B cell gene therapy in humans | Immusoft’s steps to delivering a treatment using engineered B cells. (Screen grab from Immusoft’s website) Seattle biotech startup Immusoft has received approval to begin clinical trials of its novel strategy for treating genetic disease, t... |
| Oct 14, 2021 | Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M | Immusoft CEO Sean Ainsworth. (Immusoft Photo) Seattle-based cell therapy startup Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system in a deal worth potentially more than $900 mill... |
| May 27, 2021 | Oisín raises $5M to develop treatments for ‘zombie cells’ associated with age-related diseases | Two of Oisín’s three co-founders: CEO Matthew Scholz (left) and Chief Scientific Officer John Lewis. (Oisín Photos) New funding: Seattle biotech startup Oisín Biotechnologies has raised a $5 million seed round. It’s currently developing pre... |
| May 27, 2021 | Oisìn Biotechnologies Raises $5M in Seed Funding | Oisìn Biotechnologies, a Seattle WA-based company that specializes in mitigating the effects of age-related diseases, raised $5M in seed funding. The round, which brought total funding to $9.5m, was led by Althea Group, LLC. The company int... |
| Oisin Biotechnologies | “Oisín Biotechnologies” | |
| Oisin Biotechnologies | “Oisín Biotechnologies develops genetic medicines to address age-related diseases.” |
Reviews 0
FAQ about Oisín Biotechnologies
How much funding has Oisín Biotechnologies raised?
Oisín Biotechnologies has raised $15M in total across 1 funding round.
Who has invested in Oisín Biotechnologies?
Parsers VC lists 2 investors of Oisín Biotechnologies, among them Healthspan Capital.
What has the press written about Oisín Biotechnologies?
Parsers VC has collected 9 articles mentioning Oisín Biotechnologies, among them “Этот учёный хочет постепенно заменить ваш мозг” (Oct 22, 2024) and “Oisín Biotechnologies Holds First Close of $15M Series A Financing” (Jul 25, 2024).
Is Oisín Biotechnologies still active?
Yes, Oisín Biotechnologies is active; its latest activity on Parsers VC dates from Oct 26, 2024.